Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000189 · ClinicalTrials.gov registry record · Phase 2

Gepirone vs Placebo in Treatment of Cocaine Dependence - 3

A Phase 2 study of Cocaine-Related Disorders, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 2
Development phase
41
Enrollment target
1
Study location

NCT00000189 is a Phase 2 study of Cocaine-Related Disorders that has completed, run by University of Pennsylvania. The registered enrollment target is 41 participants, below the 62-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000189, a Phase 2 study of Cocaine-Related Disorders, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 2
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects.

Conditions Studied

Interventions

  • DRUG Gepirone

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 1990-01
Est. Completion 1991-02
Phase Phase 2

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT00000189

The ClinicalTrials.gov registry entry for NCT00000189 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (34% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Gepirone is the first listed.

NCT00000189 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00000189 about?

NCT00000189 is a clinical study titled "Gepirone vs Placebo in Treatment of Cocaine Dependence - 3". The purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects.

What is the current status of trial NCT00000189?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 1990-01. Estimated completion is 1991-02.

What conditions does trial NCT00000189 study?

This clinical trial studies the following conditions: Cocaine-Related Disorders.

What interventions are being tested in trial NCT00000189?

The interventions under investigation include: Gepirone (DRUG).

Who is sponsoring clinical trial NCT00000189?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000189 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.